Response Genetics Q4 Revenues Down 13 Percent on Lower Pharma Client Business | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostic testing firm Response Genetics today reported a 13 percent drop year over year in its fourth quarter revenues.

For the three months ended Dec. 31, 2013, the Los Angeles-based company recorded revenues of $4.8 million, down from $5.5 million in Q4 2012. While Response DX test revenues were up 3 percent year over year, pharmaceutical client revenues were down 35 percent year over year, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.